Rare Diseases: Challenges and Advances in Treatment

 

To read the book for free, access it through the following link:

Rare Diseases (access the book)

Rare diseases, defined by their low prevalence and mostly of genetic origin, have evolved from being little-known and untreated pathologies to a field with significant advances. This progress is due to the development of orphan drugs, advanced therapies such as gene and cell therapies, and growing medical and social recognition. Despite persistent challenges in diagnosis, access, and cost, the outlook is increasingly promising thanks to increased research and approvals of innovative therapies by agencies such as the FDA. In this book we discuss advances in treatment, driving the development of specific drugs. I hope it is of interest to you.

Historically, these diseases were described in a fragmented way, which made them difficult to identify and treat, generating uncertainty in patients. Currently, more than 9,000 rare diseases have been identified that affect millions of people, although each one has a very low prevalence. 80% have a genetic origin, although there are also infectious, autoimmune or unknown causes. Diagnosis remains complex due to the lack of information and specialists.

Among the most studied and best-known rare diseases are: Cystic fibrosis, Duchenne muscular dystrophy, Hemophilia, Huntington's disease, Amyotrophic lateral sclerosis, Phenylketonuria and Gaucher disease. On the other hand, among the rare diseases with innovative treatments are: Spinal muscular atrophy (SMA), Hemophilia (gene therapies), Leber's congenital amaurosis (LCA), Metachromatic leukodystrophy, Gaucher disease, Lysosomal acid lipase deficiency (severe), Acute hepatic porphyria and Pompe disease.